JY
ACET icon

Jeff Yass’s Adicet Bio ACET Stock Holding History

Jeff Yass’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Buy
+19,600
New +$154K ﹤0.01% 12103
2025
Q1 		– Sell
-663
Closed -$10.2K – 12366
2024
Q4 		$10.2K Buy
+663
New +$12.5K ﹤0.01% 11983
2024
Q3 		– Sell
-1,531
Closed -$29.6K – 11853
2024
Q2 		$29.6K Buy
1,531
+387
+34% +$10.4K ﹤0.01% 11571
2024
Q1 		$43K Buy
+1,144
New +$47.3K ﹤0.01% 11612
2023
Q3 		– Sell
-669
Closed -$26K – 11918
2023
Q2 		$26K Sell
669
-12
-2% -$1.06K ﹤0.01% 11566
2023
Q1 		$62.8K Buy
+681
New +$85.5K ﹤0.01% 11589
2022
Q4 		– Sell
-5,175
Closed -$1.18M – 12257
2022
Q3 		$1.18M Buy
5,175
+3,525
+214% +$895K ﹤0.01% 6217
2022
Q2 		$385K Buy
1,650
+87
+6% +$19.1K ﹤0.01% 8887
2022
Q1 		$499K Sell
1,563
-3,406
-69% -$783K ﹤0.01% 8976
2021
Q4 		$1.39M Buy
+4,969
New +$853K ﹤0.01% 6406
2020
Q2 		– Sell
-340
Closed -$39K – 10028
2020
Q1 		$39K Buy
340
+234
+221% +$34.7K ﹤0.01% 9761
2019
Q4 		$18K Buy
+106
New +$53.7K ﹤0.01% 9496

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Jeff Yass's ACET Position: Q2 2026 in Review

Jeff Yass opened a new position in Adicet Bio (ACET) in Q2 2026: 20,650 shares worth $178K. The stake represents ﹤0.01% of the portfolio and ranks #12058 among its holdings. This is a return to the name: Jeff Yass previously reported a position in ACET as recently as Q3 2025.

Jeff Yass first reported a position in ACET in Q4 2019 and has held it in 21 quarters since. The position peaked at $1.13M in Q1 2021. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Jeff Yass held 20,650 shares of Adicet Bio worth $178K as of Q2 2026.
  • Adicet Bio was a new Jeff Yass position in Q2 2026.
  • Adicet Bio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12058 holding.
  • Jeff Yass first reported a position in Adicet Bio in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Adicet Bio position peaked at $1.13M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.